



# An Evaluation Of Orthopaedic Clinical Practice Guidelines Using The Right Checklist



Jake Xavier Checketts B.S.<sup>1</sup>, Keith Fishbeck D.O.<sup>2</sup>, Jared Scott B.S.<sup>1</sup>, Craig Cooper B.S.<sup>1</sup>, Matthew Vassar PhD<sup>1</sup>  
 Oklahoma State University Center for Health Sciences  
 Oklahoma State University Center for Health Sciences – Department of Orthopaedics

**CENTER FOR HEALTH SCIENCES**


## INTRODUCTION

The Reporting Items for practice Guidelines in Healthcare (RIGHT) checklist was developed in 2016 to address the quality of reporting in the development of clinical practice guidelines (CPGs). Building on existing framework for reporting guideline development, including the work of the EQUATOR Network, the RIGHT Working Group created a checklist of items considered essential for high-quality reporting of CPGs. The RIGHT (Reporting Items for practice Guidelines in Healthcare) checklist focuses on essential components for well-reported CPGs. The development of this checklist was performed by a multidisciplinary team of experts from 12 countries. The RIGHT checklist consists of 22 items that cover multiple domains, which includes basic information, background, evidence, recommendations, review and quality assurance, funding declaration, and management of interests.

## METHODS

Search strategies, eligibility criteria, and data abstraction were prespecified in the research protocol developed and piloted *a priori*. This study did not meet the regulatory definition of human subject research as defined in 45 CFR 46.102(d) and (f) of the Department of Health and Human Service Code of Federal Regulations and was not subject to Institutional Review Board oversight. Two of us searched the AAOS website for all 18 CPGs currently published in the field of orthopedic surgery. All CPGs were included; however, we did not include consensus statements or appropriate use criteria. Two of us independently abstracted and scored the CPGs using a piloted abstraction forms. Each score was verified by a second investigator. Disagreements were resolved by consensus between the pair. A third-party adjudication process was established in the protocol, but it was not needed.

Section/topic	No.	Item
<b>Basic information</b>		
Title/subtitle	1a	Identify the report as a guideline, that is, with "guideline(s)" or "recommendation(s)" in the title.
	1b	Describe the year of publication of the guideline.
	1c	Describe the focus of the guideline, such as screening, diagnosis, treatment, management, prevention or others.
Executive summary	2	Provide a summary of the recommendations contained in the guideline.
Abbreviations and acronyms	3	Define new or key terms, and provide a list of abbreviations and acronyms if applicable.
Corresponding developer	4	Identify at least one corresponding developer or author who can be contacted about the guideline.
<b>Background</b>		
Brief description of the health problem(s)	5	Describe the basic epidemiology of the problem, such as the prevalence/incidence, morbidity, mortality, and burden (including financial) resulting from the problem.
Aim(s) of the guideline and specific objectives	6	Describe the aim(s) of the guideline and specific objectives, such as improvement in health indicators (e.g., mortality and disease prevalence), quality of life, or cost savings.
Target population(s)	7a	Describe the primary population(s) that is addressed by the recommendation(s) in the guideline.
	7b	Describe any subgroups that are given special consideration in the guideline.
End-users and settings	8a	Describe the intended primary users of the guideline (such as primary care providers, clinical specialists, public health practitioners, program managers, and policy-makers) and other potential users of the guideline.
	8b	Describe the setting(s) for which the guideline is intended, such as primary care, low- and middle-income countries, or in-patient facilities.
Guideline development groups	9a	Describe how all contributors to the guideline development were selected and their roles and responsibilities (e.g., steering group, guideline panel, external reviewer, systematic review team, and methodologists).
	9b	List all individuals involved in developing the guideline, including their title, role(s) and institutional affiliation(s).
<b>Evidence</b>		
Healthcare questions	10a	State the key questions that were the basis for the recommendations in PICO (population, intervention, comparison, and outcome) or other format as appropriate.
	10b	Indicate how the outcomes were selected and rated.
Systematic reviews	11a	Indicate whether the guideline is based on new systematic reviews done specifically for this guideline or whether existing systematic reviews were used.
	11b	If the guideline developers used existing systematic reviews, reference these and describe how those reviews were identified and assessed (provide the search strategies and the selection criteria, and describe how the risk of bias was evaluated) and whether they were updated.
Assessment of the certainty of the body of evidence	12	Describe the approach used to assess the certainty of the body of evidence.
<b>Recommendations</b>		
Recommendations	13a	Provide clear, precise, and actionable recommendations.
	13b	Present separate recommendations for important subgroups if the evidence suggests that there are important differences in factors influencing recommendations, particularly the balance of benefits and harms across subgroups.
	13c	Indicate the strength of recommendations and the certainty of the supporting evidence.
Rationale/explanation for recommendations	14a	Describe whether values and preferences of the target population(s) were considered in the formulation of each recommendation. If yes, describe the approaches and methods used to elicit or identify these values and preferences. If values and preferences were not considered, provide an explanation.
	14b	Describe whether cost and resource implications were considered in the formulation of recommendations. If yes, describe the specific approaches and methods used (such as cost-effectiveness analysis) and summarize the results. If resource issues were not considered, provide an explanation.
Evidence to decision process	15a	Describe the process and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).
	15b	Describe the process and approaches used by the guideline development group to make decisions, particularly the formulation of recommendations (such as how consensus was defined and achieved and whether voting was used).
<b>Review and quality assurance</b>		
External review	16	Indicate whether the draft guideline underwent independent review and, if so, how this was executed and the comments considered and addressed.
Quality assurance	17	Indicate whether the guideline was subjected to a quality assurance process. If yes, describe the process.
<b>Funding, declaration and management of interests</b>		
Funding source(s) and role(s) of the funder	18a	Describe the specific sources of funding for all stages of guideline development.
	18b	Describe the role of funder(s) in the different stages of guideline development and in the dissemination and implementation of the recommendations.
Declaration and management of interest	19a	Describe what types of conflicts (financial and non-financial) were relevant to guideline development.
	19b	Describe how conflicts of interest were evaluated and managed and how users of the guideline can access the declarations.
<b>Other information</b>		
Access	20	Describe where the guideline, its appendices, and other related documents can be accessed.
Suggestions for further research	21	Describe the gaps in the evidence and/or provide suggestions for future research.
Limitations of the guideline	22	Describe any limitations in the guideline development process (such as the development groups were not multidisciplinary or patients' values and preferences were not sought), and indicate how these limitations might have affected the validity of the recommendations.



## RESULTS

We retrieved all 18 guidelines, and all guidelines were eligible for evaluation by the RIGHT checklist. Of the 35 criteria, 23 (65.7%) were met across all AAOS guidelines. Of the 35 criteria, 6 (17.1%) were not met by any of the AAOS guidelines (Figure 1, Table 1). These include item 5, which recommends that the specific aims of the guideline be described; item 8b, which recommends that the setting that each guideline is intended for be described; item 9a, which recommends a detailed accounting of how each guideline member was selected as well as their role and responsibilities; item 14a, which recommends that a description of whether consideration was given to the values and preferences of the target population; item 18b, which recommends that the role of the funding sources of the guideline be described (the AAOS guidelines state the source of funding but not the role of the funding source); and item 22, which recommends that the limitations in the guideline development process be described.

## CONCLUSION

Overall, the AAOS guidelines addressed many important recommendations within the RIGHT checklist. Providing clear and precise recommendations within the guideline will assist end-users in more efficiently implementing the guidelines in practice. Through the identification of the strengths and weaknesses in current guidelines, future guidelines can be more effectively implemented and more easily communicated to end-users. These factors will lead to greater adherence, ultimately leading to more evidence-based care in orthopaedic surgery.